Author(s) |
(Date) |
Paper Title |
Citation |
Model Type |
Applications |
Full Text |
| Jo DH, et al. Mouse over for full list Jo DH, Lee JH, Jun HJ, Kim J, Wen Q, Hoang MH, Yu YS, Kim JH, Lee SJ |
(2015) | Gene expression profiles of primary retinal pigment epithelial cells from apolipoprotein E knockout and human apolipoprotein E2 transgenic mice. | Genet. Mol. Res. 14(1):1855-67 | Knock out, Knock in |
Metabolism | |
| Tagalakis AD, et al. Mouse over for full list Tagalakis AD, Graham IR, Riddell DR, Dickson JG, Owen JS |
(2001) | Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty. | J. Biol. Chem. 276(16):13226-30 | Knock in |
Metabolism, Neuroscience, Alzheimer's | |
| Malek G, et al. Mouse over for full list Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, Toth CA, Sullivan PM, Bowes Rickman C |
(2005) | Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. | Proc. Natl. Acad. Sci. U.S.A. 102(33):11900-5 | Neuroscience | ||
| Knouff C, et al. Mouse over for full list Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N |
(1999) | Apo E structure determines VLDL clearance and atherosclerosis risk in mice. | J. Clin. Invest. 103(11):1579-86 | |||
| Gerritsen G, et al. Mouse over for full list Gerritsen G, Kypreos KE, van der Zee A, Teusink B, Zannis VI, Havekes LM, van Dijk KW |
(2003) | Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain. | J. Lipid Res. 44(2):408-14 | |||
| Sullivan PM, et al. Mouse over for full list Sullivan PM, Mezdour H, Quarfordt SH, Maeda N |
(1998) | Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. | J. Clin. Invest. 102(1):130-5 |
